IP Library › Granted Patent US 10,005,765
Granted Patent B2
US 10,005,765 · App. 15/126,997 · Granted Jun 26, 2018

Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer

Inventor: Yun Long (San Diego, CA)
Assignee: Capella Therapeutics, Inc.
C07D409/14A61K31/55C07D223/04C07D401/14C07D403/04C07D403/12C07D403/14C07D405/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,005,765
App. No.
15/126,997
Granted
Jun 26, 2018
Kind
B2
Abstract

Provided herein are benzimidazole derivatives, for example, of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

Claims (93)

1. A compound selected from:

and single enantiomers, racemic mixtures, mixtures of diastereomers, and isotopic variants thereof; and pharmaceutically acceptable salts, solvates, and prodrugs thereof.

2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

3. The pharmaceutical composition of claim 2 , wherein the composition is formulated for oral, nasal, bronchial, or topical administration.

4. The pharmaceutical composition of claim 2 , wherein the composition is formulated as a single dosage form.

5. The pharmaceutical composition of claim 2 , wherein the composition is formulated as oral, parenteral, nasal, respiratory, pulmonary, or intravenous dosage form.

6. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition is in an oral dosage form.

7. The pharmaceutical composition of claim 6 , wherein the oral dosage form is a tablet or capsule.

8. The pharmaceutical composition of claim 2 , further comprising a second therapeutic agent.

9. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

15. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

16. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

20. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

21. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

22. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

23. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

24. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

25. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

26. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

27. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

28. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

29. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

30. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

31. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

32. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

33. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

34. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

35. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

36. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

37. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

38. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

39. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

40. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

41. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

42. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

43. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

44. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

45. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

46. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

47. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

48. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

49. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

50. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2018
From: LONG, YUN
To: CAPELLA THERAPEUTICS, INC.
Reel/Frame 047547/0698 →
Continuity (2)
Provisional Application 61968225 · Mar 20, 2014
Related Publication 20170183330A1 · Jun 29, 2017